Strides Pharma Science has announced a major leadership reshuffle to strengthen its executive management team. Effective June 1, 2026, Venkata Seetharama Raju Pakalapati (Ramaraju PVS) will join the Board as an Executive Director. Additionally, Aditya Arun Kumar transitions from his executive role to serve as a Non-Executive Director. These strategic changes reflect the company’s commitment to professionalizing its management and fostering robust internal leadership succession.
Board of Directors Transition
As part of a comprehensive succession planning framework, the Board of Directors has approved the elevation of Venkata Seetharama Raju Pakalapati to Executive Director. Ramaraju, who currently serves as Chief Operating Officer, will also be designated as a Key Managerial Personnel (KMP) starting June 1, 2026. His new role will involve overseeing global technical operations, including manufacturing, supply chain, and digital initiatives.
In a related move, Aditya Arun Kumar has decided to step down from his role as Executive Director – Business Development to support the promoter group’s vision of professionalizing company management. He will continue his association with the company, transitioning to a Non-Executive Director role effective June 1, 2026, where he will provide ongoing strategic oversight.
Management and Leadership Appointments
The company also announced significant updates to its senior leadership team to bolster organizational efficiency. Nandini Matiyani, currently Executive VP – HR, has been redesignated as Group CHRO and nominated as Senior Management Personnel (SMP). Additionally, Ariff Khan, Executive VP – Manufacturing Operations, has been nominated as SMP. Both appointments will take effect on June 1, 2026.
Strategic Outlook
These appointments and designations align with the company’s long-term growth strategy. By optimizing the leadership structure and promoting internal talent, Strides aims to drive operational excellence and sustainable expansion across its global business units. These changes ensure that the company remains well-positioned to meet the evolving demands of the pharmaceutical and healthcare sectors.
Source: BSE
